title: [Impact of gonadotropins in women suffering from cancer].
abstract: The role of gonadotropins in the genesis of malignant diseases, in particular gynecologic cancers, is still controversial. The production of ovarian steroids, as a consequence of FSH and LH actions, may constitute a bias to draw reliable conclusions. Over the past decades, the use of exogenous gonadotropins has markedly increased in cancer patients, candidates for fertility preservation, and in survivors facing infertility as a consequence of gonadotoxic treatments. In gynecologic cancers, high serum estradiol levels may be problematic and can therefore be overcome by specific protocols of ovarian stimulation. However, exogenous gonadotropin administration in cancer patients should systematically be included in a multidisciplinary approach. The present article discusses the possible role of gonadotropins as tumorigenic factors and the use of exogenous gonadotropins in females suffering from cancer.
authors.affiliation: Hôpital Jean-Verdier, service de médecine de la reproduction, avenue du 14-Juillet, 93140 Bondy, France.
authors.forename: Constance
authors.initials: C
authors.lastname: Valdelièvre
authors.affiliation: Hôpital Jean-Verdier, service de médecine de la reproduction, avenue du 14-Juillet, 93140 Bondy, France; Université Paris XIII, 93000 Bobigny, France.
authors.forename: Charlotte
authors.initials: C
authors.lastname: Sonigo
authors.affiliation: Hôpital Jean-Verdier, service de médecine de la reproduction, avenue du 14-Juillet, 93140 Bondy, France.
authors.forename: Marjorie
authors.initials: M
authors.lastname: Comtet
authors.affiliation: Hôpital Jean-Verdier, service de médecine de la reproduction, avenue du 14-Juillet, 93140 Bondy, France.
authors.forename: Cynthia
authors.initials: C
authors.lastname: Simon
authors.affiliation: Hôpital Jean-Verdier, service de médecine de la reproduction, avenue du 14-Juillet, 93140 Bondy, France.
authors.forename: Sarah
authors.initials: S
authors.lastname: Eskenazi
authors.affiliation: Hôpital Jean-Verdier, service de médecine de la reproduction, avenue du 14-Juillet, 93140 Bondy, France; Université Paris XIII, 93000 Bobigny, France; Université Paris-Diderot, unité Inserm U1133, 75013 Paris, France. Electronic address: michael.grynberg@aphp.fr.
authors.forename: Michaël
authors.initials: M
authors.lastname: Grynberg
mesh_terms: D000328:Adult; D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D059247:Fertility Preservation / Q000379:methods*; D005640:Follicle Stimulating Hormone / Q000502:physiology; D005833:Genital Neoplasms, Female / Q000209:etiology*; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000378:metabolism / Q000627:therapeutic use; D006062:Gonadotropins / Q000009:adverse effects* / Q000502:physiology*; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy / Q000209:etiology; D007986:Luteinizing Hormone / Q000502:physiology; D009369:Neoplasms / Q000209:etiology; D010062:Ovulation Induction / Q000009:adverse effects / Q000379:methods; D011962:Receptors, FSH / Q000378:metabolism
chemical_list: D006062:Gonadotropins; D011962:Receptors, FSH; D007987:Gonadotropin-Releasing Hormone; C083781:LHRH, Ala(6)-Gly(10)-ethylamide-; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone
keywords: Cancer; FIV; FSH; Gonadotrophines; Gonadotropins; IVF-ET; Malignant tumors; Ovarian stimulation; Stimulation ovarienne; Tumeurs malignes